TY - JOUR
T1 - EUFOREA consensus on biologics for CRSwNP with or without asthma
AU - Fokkens, Wytske J.
AU - Lund, Valerie
AU - Bachert, Claus
AU - Mullol, Joaquim
AU - Bjermer, Leif
AU - Bousquet, Jean
AU - Canonica, Giorgio W.
AU - Deneyer, Lauren
AU - Desrosiers, Martin
AU - Diamant, Zuzana
AU - Han, Joseph
AU - Heffler, Enrico
AU - Hopkins, Claire
AU - Jankowski, Roger
AU - Joos, Guy
AU - Knill, Andrew
AU - Lee, Jivianne
AU - Lee, Stella E.
AU - Mariën, Gert
AU - Pugin, Benoit
AU - Senior, Brent
AU - Seys, Sven F.
AU - Hellings, Peter W.
N1 - © 2019 The Authors Allergy Published by John Wiley & Sons Ltd.
PY - 2019/12
Y1 - 2019/12
N2 - Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.
AB - Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85069662686&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31090937
U2 - https://doi.org/10.1111/all.13875
DO - https://doi.org/10.1111/all.13875
M3 - Review article
C2 - 31090937
SN - 0105-4538
VL - 74
SP - 2312
EP - 2319
JO - Allergy
JF - Allergy
IS - 12
ER -